Anavex life sciences to present at the 4th annual evercore isi healthconx conference

New york, nov. 29, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that its president and chief executive officer, christopher u. missling, phd, is scheduled to participate in a virtual fireside chat at the 4th annual evercore isi healthconx conference on december 2, 2021 at 12:10 p.m. et.
AVXL Ratings Summary
AVXL Quant Ranking